126 related articles for article (PubMed ID: 8020535)
1. Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in the dog.
Wikberg T; Ottoila P; Taskinen J
Eur J Drug Metab Pharmacokinet; 1993; 18(4):359-67. PubMed ID: 8020535
[TBL] [Abstract][Full Text] [Related]
2. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans.
Wikberg T; Vuorela A; Ottoila P; Taskinen J
Drug Metab Dispos; 1993; 21(1):81-92. PubMed ID: 8095232
[TBL] [Abstract][Full Text] [Related]
3. Metabolite profiles of two [14C]-labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bile.
Wikberg T; Vuorela A
Eur J Drug Metab Pharmacokinet; 1994; 19(2):125-35. PubMed ID: 8001593
[TBL] [Abstract][Full Text] [Related]
4. Identification of major metabolites of the catechol-O-methyltransferase inhibitor nitecapone in the rat and dog.
Wikberg T; Taskinen J
Drug Metab Dispos; 1993; 21(2):325-33. PubMed ID: 8097704
[TBL] [Abstract][Full Text] [Related]
5. Identification of major metabolites of the catechol-O-methyltransferase-inhibitor nitecapone in human urine.
Taskinen J; Wikberg T; Ottoila P; Kanner L; Lotta T; Pippuri A; Bäckström R
Drug Metab Dispos; 1991; 19(1):178-83. PubMed ID: 1673395
[TBL] [Abstract][Full Text] [Related]
6. Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine.
Karlsson M; Wikberg T
J Pharm Biomed Anal; 1992 Aug; 10(8):593-600. PubMed ID: 1463794
[TBL] [Abstract][Full Text] [Related]
7. Enzyme-assisted synthesis and structural characterization of nitrocatechol glucuronides.
Luukkanen L; Kilpeläinen I; Kangas H; Ottoila P; Elovaara E; Taskinen J
Bioconjug Chem; 1999; 10(1):150-4. PubMed ID: 9893978
[TBL] [Abstract][Full Text] [Related]
8. Micellar electrokinetic capillary chromatography method for direct determination of glucuronides of entacapone and its (Z)-isomer in human urine.
Lehtonen P; Lehtinen S; Mälkki-Laine L; Wikberg T
J Chromatogr A; 1999 Mar; 836(1):173-88. PubMed ID: 10220913
[TBL] [Abstract][Full Text] [Related]
9. Separation of the glucuronides of entacapone and its (Z)-isomer in urine by micellar electrokinetic capillary chromatography.
Lehtonen P; Mälkki-Laine L; Wikberg T
J Chromatogr B Biomed Sci Appl; 1999 Jan; 721(1):127-34. PubMed ID: 10027643
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ
Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372
[TBL] [Abstract][Full Text] [Related]
11. LC/MS/MS study for identification of entacapone degradation product obtained by photodegradation kinetics.
Paim CS; Palma EC; Malesuik MD; Steppe M
J AOAC Int; 2010; 93(6):1856-61. PubMed ID: 21313812
[TBL] [Abstract][Full Text] [Related]
12. Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability.
Alqahtani S; Kaddoumi A
Biopharm Drug Dispos; 2015 Dec; 36(9):587-602. PubMed ID: 26295926
[TBL] [Abstract][Full Text] [Related]
13. Iron(III)-chelating properties of the novel catechol O-methyltransferase inhibitor entacapone in aqueous solution.
Orama M; Tilus P; Taskinen J; Lotta T
J Pharm Sci; 1997 Jul; 86(7):827-31. PubMed ID: 9232524
[TBL] [Abstract][Full Text] [Related]
14. Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's disease.
Li LS; Liu CZ; Xu JD; Zheng LF; Feng XY; Zhang Y; Zhu JX
World J Gastroenterol; 2015 Mar; 21(12):3509-18. PubMed ID: 25834315
[TBL] [Abstract][Full Text] [Related]
15. Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees.
Riska PS; Joseph DP; Dinallo RM; Davidson WC; Keirns JJ; Hattox SE
Drug Metab Dispos; 1999 Dec; 27(12):1434-47. PubMed ID: 10570025
[TBL] [Abstract][Full Text] [Related]
16. Development of characterization methods for entacapone in a pharmaceutical bulk.
Soukhova N; Kassymbek Z; Bradby S; Martin-Esker A; White P; Wahab S
J Pharm Biomed Anal; 2011 Mar; 54(4):860-5. PubMed ID: 21112716
[TBL] [Abstract][Full Text] [Related]
17. Identification of urinary catechol and methylated catechol metabolites of phenytoin in humans, monkeys, and dogs by GLC and GLC-mass spectrometry.
Midha KK; Hindmarsh KW; McGilveray IJ; Cooper JK
J Pharm Sci; 1977 Nov; 66(11):1596-602. PubMed ID: 410919
[TBL] [Abstract][Full Text] [Related]
18. Biotransformation of the partial beta-agonist doxaminol in dog.
Neidlein R; Volland C; Strein K
Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):130-6. PubMed ID: 1970733
[TBL] [Abstract][Full Text] [Related]
19. Determination of n-hexane metabolites by liquid chromatography/mass spectrometry. 2. Glucuronide-conjugated metabolites in untreated urine samples by electrospray ionization.
Manini P; Andreoli R; Mutti A; Bergamaschi E; Niessen WM
Rapid Commun Mass Spectrom; 1998; 12(21):1615-24. PubMed ID: 9807835
[TBL] [Abstract][Full Text] [Related]
20. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.
Fischer JJ; Michaelis S; Schrey AK; Graebner OG; Glinski M; Dreger M; Kroll F; Koester H
Toxicol Sci; 2010 Jan; 113(1):243-53. PubMed ID: 19783845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
